SILO PHARMA, INC. Disposal Group, Including Discontinued Operation, Gross Profit (Loss)
SILO PHARMA, INC. (SILO) reported Disposal Group, Including Discontinued Operation, Gross Profit (Loss) of -$1.08 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss · last filed 2024-03-25
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for the quarter ending 2022-12-31 was -$2.16K.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for the quarter ending 2022-09-30 was $2.16K, a 74.90% decline year-over-year.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for the quarter ending 2022-03-31 was -$1.08K.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for fiscal 2022 was -$1.08K, a 106.93% decline from fiscal 2021.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for fiscal 2021 was $15.58K.
- SILO PHARMA, INC. disposal group, including discontinued operation, gross profit (loss) for fiscal 2020 was -$141.50K.
| Period end | Disposal Group, Including Discontinued Operation, Gross Profit (Loss) 3 month | Disposal Group, Including Discontinued Operation, Gross Profit (Loss) 6 month | Disposal Group, Including Discontinued Operation, Gross Profit (Loss) 9 month | Disposal Group, Including Discontinued Operation, Gross Profit (Loss) 9 month as first filed | Disposal Group, Including Discontinued Operation, Gross Profit (Loss) 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | -$2.16K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | -$1.08K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $2.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.16K derived: sum of 2 quarters · filed 2023-11-13 | $1.08K 10-Q · filed 2023-11-13 | -$1.08K 10-Q · filed 2022-11-10 | -$3.88K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.08K 10-Q · filed 2023-08-11 | -$6.04K derived: sum of 3 quarters · filed 2023-08-11 | $2.56K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$1.08K 10-Q · filed 2023-05-12 | -$6.04K derived: sum of 2 quarters · filed 2023-05-12 | $2.56K derived: sum of 3 quarters · filed 2023-05-12 | $15.58K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | -$4.96K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $3.64K derived: sum of 2 quarters · filed 2023-03-24 | $16.66K derived: sum of 3 quarters · filed 2023-03-24 | $15.58K 10-K · filed 2023-03-24 | |
| 2021-09-30 | $8.60K 10-Q · filed 2021-11-10 | $21.62K derived: sum of 2 quarters · filed 2022-08-01 | $20.54K 10-Q · filed 2022-11-10 | -$108.89K derived: sum of 4 quarters · filed 2022-08-01 | |
| 2021-06-30 | $13.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $11.95K 10-Q · filed 2022-08-01 | -$117.49K derived: sum of 3 quarters · filed 2022-08-01 | -$130.65K derived: sum of 4 quarters · filed 2022-08-01 | |
| 2021-03-31 | -$1.08K 10-Q · filed 2022-05-13 | -$130.51K derived: sum of 2 quarters · filed 2022-05-13 | -$143.68K derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$129.43K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$142.60K derived: sum of 2 quarters · filed 2022-03-28 | -$141.50K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | -$13.16K 10-Q · filed 2021-11-10 | -$12.07K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |